Colombia to produce its own vaccine against covid-19; This is the development in the country

VaxThera, a Colombian biotechnology company focused on the development of vaccines and biologics that contribute to the health jurisdiction of the country and the region, announced that The United States Trademark and Trademark Office (USPTO) granted the patent for its universal coronavirus vaccine.

This vaccine includes a mosaic protein that allows a broad protective layer against different coronavirus variants.

“This achievement is an important milestone for VaxThera and demonstrates Colombia’s ability to develop new drugs against threats and the importance of protecting its intellectual property rights.” In addition, this application was filed under the Patent Cooperation Treaty (PCT), which allows us to simultaneously seek the protection of this technique in other countries such as Colombia, Brazil, India, South Africa and Europe,” said Jorge E. Osorio, president of VaxThera.

Obtaining this patent contributes to the task of improving the quality of life in Colombia and Latin America and offers the region the health independence it needs to face diseases in the future time.

It should be noted, Since 1998, vaccines have not been produced in Colombia and although the Expanded Program on Immunization (EPI) includes 21 vaccines that protect against 26 diseases, none of them are produced locally.

Local production contributes to the recovery of the national pharmaceutical industry, because in addition to establishing a fair, efficient and effective distribution for the entire country, access to products aimed at preventing diseases that affect public health is developed. All this represents a contribution to the economy, through employment, the generation of resources from the export of biological products and the reduction of costs for those who distribute it.

Obtaining this patent takes place after a rigorous technical process of more than three years, which has shown that the invention of this vaccine is new and has industrial application. Daniela Lopera, Director of Legal and Regulatory Affairs at VaxThera, clarifies that “patents are titles that are very strategically appropriate for companies in the technology sector, especially those in the pharmaceutical and biotechnology sectors , as they are an important means of protecting their inventions and inventions. to encourage their research and development activities.”

To achieve this significant achievement, VaxThera had the support, advice and guidance of Sterne, Kessler, Goldstein & Fox PLLC, American company expert on intellectual property issues in the biotechnology sector.

“The only asset a biotech research startup like VaxThera has at the beginning of its corporate life is its intellectual property. This patent protects that intellectual property in the United States market and adds global value to the contributions of the company’s innovative scientists,” said Dr. Jorge Goldstein, the founder of the company, is considered one of the pioneers in copyright law, biotechnology patents in the United States.

VaxThera, as a Colombian company that has Seguros SURA as a founding partner, works with its own capabilities, collaborative networks, modern technology and national and international experts that help strengthen the transfer of knowledge to achieve vaccine autonomy and thus prepare. for future pandemics. The granted patent allows the Company to have exclusivity over the invention for 20 years and thus continue on the path to the reactivation of the health sector by producing vaccines and bio -knowledge locally.